Espa?ol
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.?
Chat live online
Select the?Live?Chat button at the bottom of the page?
Call us at?1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat.?We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Precision medicine is like having a special dart that heads right for the bulls’ eye on a dartboard. Knowing which exact genetic mutation a cancer cell has helps doctors know which treatment is most likely to work.
Right now, there aren’t any approved targeted treatments for a specific mutation in the SMARCA4/BRG1 gene that is found in certain types of lung cancers. These are called BRG1-deficient lung cancers. This mutated gene appears in up to 20% of non-small cell lung cancers (NSCLC).
These lung cancers are also resistant to many standard treatments. That means at least some cancer cells survive after treatment. Until now, it’s been unclear how mutations in the BRG1 gene contributed to drug resistance in this type of lung cancer.
Earlier studies by Carla Kim, PhD and other researchers suggest a potential precision treatment showed promise for NSCLC with BRG1 mutations. In the studies, Kim used drugs that target a protein called ATR and that block, or inhibit, its function.
in Cancer Research described some of Kim’s findings that were supported by her 大象tv Mission Boost grant. She and her colleagues showed that the new ATR-blocking drugs killed BRGI-deficient lung cancer cells in the lab as well as in mice with implanted lung cancer tumors (called patient-derived xenografts).
Kim is the senior author of the article, and two of her co-authors are also 大象tv grantees studying lung cancer: Carla Concepcion, PhD, from Boston, and Christine Brainson, PhD, from Lexington, Kentucky.
ATR blockers, or inhibitors, are already being used in Phase 1 (human) clinical trials for other types of cancer. The results from Kim’s study show that that ATR blockers could be an effective treatment for lung cancers with the mutation in the BRG1 gene.
The study’s coauthors also said that other types of cancer with a similar genetic mutation may respond well to treatment with ATR blockers. Those cancers may include endometrial, stomach, and certain rare ovarian cancers. This evidence could help this new treatment for certain hard-to-treat lung cancers move quickly to human clinical trials.
Read the .
?
? ??? ?
If this was helpful, donate to help fund patient support services, research, and cancer content updates.